Drug Profile
GRANITE 001
Alternative Names: GRANITE; GRANITE-001; GRT-C901/GRT-R902; TSNA-specific-immunotherapy-Gritstone bio; Tumour-specific-immunotherapy-Gritstone bioLatest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator Gritstone Oncology
- Developer Bristol-Myers Squibb; Gritstone bio
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines; Synthetic vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Colorectal cancer
- Phase I/II Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
Most Recent Events
- 16 Aug 2023 9395992: Updated KDM (deal with Friends of Cancer Research has not been covered since its an NIO)
- 09 Mar 2023 Updated efficacy data from a phase I/II trial in Colorectal cancer released by Gritstone bio
- 13 Dec 2022 Gritstone bio has patent protection for cancer vaccine candidates (GRANITE) and antigen-encoding samRNA vectors in USA